PON1 and lung cancer: As illustrated in Fig. 4, the atovaquone-treated Fhit-deficient E1 lung cancer cells showed significantly reduced viability, while the Fhit-positive cells were unaffected by atovaquone (see Fig. 1c for Fhit expression in these cells after Pon A treatment).